RSS   Newsletter   Contact   Advertise with us
Post Online Media

Deciphera elects Steven L. Hoerter to board

Deciphera PharmaceuticalsDeciphera Pharmaceuticalss, a clinical-stage biotechnology company, elected Steven L. Hoerter, chief commercial officer at Agios Pharmaceuticals, to its board.
Mr. Hoerter will serve as an independent director and a member of the Nominating and Corporate Governance Committee.

Mr. Hoerter has served as Chief Commercial Officer of Agios since early 2016 where he built and leads the team responsible for the commercialization of the company’s portfolio of first-in-class medicines for oncology and rare genetic diseases.

Mr. Hoerter has more than 25 years of global pharmaceutical and biotechnology experience, having held senior positions at leading oncology companies.

Prior to joining Agios, he was executive vice president and Chief Commercial Officer at Clovis Oncology, Inc., where he built and led the company’s commercial organization.

Before joining Clovis, he was General Manager and Management Center Head at Roche for the Sub-Saharan Africa and Indian Ocean Region.

From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business.

Prior to that, he held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe, and Africa.

Mr. Hoerter was a member of the Board of Directors of Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, until the company’s acquisition by Roche earlier this year.

Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University.


 LATEST MOVES FROM Massachusetts 


POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.